search
Back to results

Condition of Approval Study (COAST)

Primary Purpose

Lumbar Spinal Stenosis

Status
Terminated
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
X-STOP PEEK
Sponsored by
Medtronic Spine LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Lumbar Spinal Stenosis focused on measuring Lumbar Spinal Stenosis, X-STOP Spacer, Interspinous process decompression, Neurogenic Intermittent Claudication

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. has a baseline score >2.0 in the Physical Function (PF) domain of the Zurich Claudication Questionnaire
  2. is 50 years old or older
  3. has leg/buttock/groin pain with or without back pain NOTE: Leg/buttock/groin pain must be completely relieved when flexed such as when sitting in a chair. If back pain is also present, it must be partially relieved when flexed.
  4. can sit for 50 minutes without pain
  5. can walk 50 feet or more
  6. has a confirmed diagnosis of neurogenic intermittent claudication secondary to lumbar spinal stenosis, with X-Ray, MRI and/or CT evidence of thickened ligamentum flavum, narrowed lateral recess and/or central canal narrowing
  7. has completed at least six months of conservative care therapy which may include but is not limited to physical therapy, bracing, systemic or injected medications
  8. has signed a patient informed consent document
  9. is physically and mentally willing and able or has a caregiver who can comply with the postoperative and routinely scheduled clinical and radiographic evaluations
  10. lives in the immediate area and has no plans to relocate to another geographic area before completion of the study or lives outside the immediate area and will comply with the scheduled postoperative visits with a prearranged and designated physician

Exclusion Criteria:

  1. has a baseline score less than or equal to 2.0 in the Physical Function (PF) domain of the Zurich Claudication Questionnaire
  2. cannot sit for 50 minutes
  3. cannot walk more than 50 feet
  4. has unremitting pain in any spinal position
  5. has axial back pain only without leg/buttock/groin pain
  6. has a fixed motor deficit
  7. has cauda equina syndrome defined as neural compression causing neurogenic bowel (rectal incontinence) or bladder (bladder retention or incontinence) dysfunction
  8. has severe symptomatic lumbar spinal stenosis at more than two levels
  9. has significant instability of the lumbar spine, e.g., isthmic spondylolisthesis or degenerative spondylolisthesis greater than grade 1 (on a scale of 1 to 4)
  10. has an ankylosed segment at the affected level(s);
  11. has significant scoliosis (Cobb angle is greater than 25 degrees)
  12. has an acute fracture of the spinous process or pars interarticularis
  13. has sustained pathologic fractures of the vertebrae or multiple fractures of the vertebrae and /or hips
  14. has severe osteoporosis of the spine or hip, defined as bone mineral density (BMD) in the spine or hip more than 2.5 SD below the mean of adult normals in the presence of one or more fragility fractures
  15. has Paget's disease at the involved segment(s) or metastasis to the vertebrae
  16. has had any surgery of the lumbar spine
  17. has significant peripheral neuropathy demonstrated by nerve conduction velocity tests
  18. has acute denervation secondary to radiculopathy, as shown by EMG
  19. has significant peripheral vascular disease characterized by diminished dorsalis pedus or tibial pulses
  20. has extreme obesity as defined by a Body Mass Index (BMI) greater than 40 kg/m2
  21. has an active systemic infection or infection localized to the site of implantation
  22. has an active systemic disease such as AIDS, HIV, hepatitis, etc.
  23. has a medical condition that may interfere with postoperative management and follow-up, or may result in patient death prior to study completion (e.g., Alzheimer's disease, unstable cardiac disease, active malignancy)
  24. has a recent history of narcotic abuse (i.e., within last 3 years)
  25. has a known allergy to titanium,titanium alloy, or polyetheretherketone
  26. is immunologically suppressed, or has received or is receiving steroids at any dose daily for more than one month within the last 12 months
  27. is currently involved in a study of another investigational product that may affect the outcome of this study
  28. is pregnant or planning to become pregnant during the study period
  29. cannot undergo MRI or tolerate closed MRI scanning.

Sites / Locations

  • The Kirklin Clinic - UAB Medical
  • Tucson Orthopaedic Institute-East Office
  • Tucson Orthopaedic Institute-Northwest Office
  • Silicon Valley Spine Institute
  • UC Davis Spine Center
  • UCLA Comprehensive Spine Center
  • Colorado Neurosurgery Associates, P.C.
  • Panaorama Orthopedics and Spine Center
  • Yale School of Medicine, Dept. of Orthopaedics
  • George Washington University Hospital Medical Facility Associates
  • Pinnacle Orthopedics
  • Orthopaedic Center of Southern Illinois
  • University of Kentucky, Dept of Neurosurgery
  • Spine Institute of Louisiana
  • Drisko, Fee & Parkins, P.C.
  • UpState Orthopedics
  • Mayfield Clinic
  • The Center Orthopedic & Neurosurgical Care & Research
  • NeuroSpine Institute
  • OrthopaediCare
  • Texas Back Institute
  • Neurosurgical Associates of San Antonio
  • Scott & White Memorial Hospital & Scott, Sherwood & Brindley Foundation

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

X-STOP PEEK

Arm Description

In this arm, patients will undergo X-STOP PEEK surgery.

Outcomes

Primary Outcome Measures

Treatment Success Rate at 24 Months
Treatment success rate is reported as the percentage of participants who met all of the following criteria: Clinically significant improvement (by at least 0.5 points) in the Symptom Severity (SS) domain of the Zurich Claudication Questionnaire (ZCQ) compared to preoperative baseline Clinically significant improvement (by at least 0.5 points) in the Physical Function (PF) domain of the ZCQ compared to pre-operative baseline Patient satisfaction with treatment defined as a Patient Satisfaction (PS) score < 2.5 No additional surgery for lumbar stenosis performed Maintenance of distraction No dislodgement of the implant No device-related complications

Secondary Outcome Measures

Treatment Success Rate at 60 Months
Treatment success rate is reported as the percentage of participants who met all of the following criteria: Clinically significant improvement (by at least 0.5 points) in the Symptom Severity (SS) domain of the ZCQ compared to preoperative baseline Clinically significant improvement (by at least 0.5 points) in the Physical Function (PF) domain of the ZCQ compared to pre-operative baseline Patient satisfaction with treatment defined as a Patient Satisfaction (PS) score < 2.5 No additional surgery for lumbar stenosis performed Maintenance of distraction No dislodgement of the implant No device-related complications
Symptom Severity (SS) Scores Measured by Zurich Claudication Questionnaire (ZCQ)
ZCQ is a validated outcomes instrument specific to lumbar spinal stenosis, and captures data in 3 distinct domains: SS, PF, and post-treatment PS. SS Score is based on seven questions (overall pain, pain frequency, pain in the back, pain in the leg, numbness, weakness, and balanced disturbance) in ZCQ. The first 6 questions are scored 1 to 5. Balance disturbance is scored in a 1-3-5 scale. The SS score is the mean of all answered items in the questionnaire, ranging from 1 to 5. A lower score represents a better outcome/condition. If more than two items were missing, the SS score was considered as missing.
Success Rate in Symptom Severity (SS) Domain of Zurich Claudication Questionnaire (ZCQ)
Success rate in SS domain of ZCQ is reported as percentage of participants who had success in SS domain of the ZCQ. The SS success was defined as clinically significant improvement by at least 0.5 point in SS score compared to preoperative baseline.
Physical Function (PF) Scores Measured by Zurich Claudication Questionnaire (ZCQ)
PF score is the mean score of five physical function questions of ZCQ, ranging from 1 to 4. A lower score represents a better outcome/condition. If more than one item were missing, the PF score was considered as missing.
Success Rate in Physical Function (PF) Domain of Zurich Claudication Questionnaire (ZCQ)
Success rate in PF domain of ZCQ is reported as percentage of participants who had success in PF domain of ZCQ. The PF success was defined as clinically significant improvement by at least 0.5 points in PF score compared to preoperative baseline.
Patient Satisfaction (PS) Scores Measured by Zurich Claudication Questionnaire (ZCQ) at Post Treatment
PS score is the mean score of 6 questions of ZCQ, ranging from 1 to 4 if the number of responses exceeded four. A lower score represents a better outcome. Patients with PS score less than 2.5 at postoperative evaluation were considered positive, which implied that patients were satisfied with their treatment.
Success Rate in Patient Satisfaction (PS) Domain of Zurich Claudication Questionnaire (ZCQ) at Post Treatment
Success rate in PS domain of ZCQ at post treatment is reported as the percentage of participants who had success in PS domain of ZCQ. The PS success was defined as PS score less than 2.5.
Oswestry Disability Index (ODI) Score
ODI Questionnaire was used to assess patient back function. The ODI score ranges from 0-100. The best score is 0 (no disability) and worst is 100 (maximum disability).
General Health Status -- SF-36 PCS
The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) was used to assess general health status. The SF-36 results were summarized into two components, a physical component summary (PCS) and a mental component summary (MCS). The score for PCS is between 0 and 100, with higher scores denoting better quality of life.
General Health Status -- SF-36 MCS
MCS score is between 0 and 100, with higher scores denoting better quality of life.
Back Pain in Numerical Rating Scales (NRS)
Back pain was measured using NRS. Patients rated their back pain on a scale from 0-10, with a score of 0 representing "no pain" and a score of 10 representing "pain as bad as it could be."
Left Leg Pain in Numerical Rating Scales (NRS)
Left leg pain was measured using NRS. Patients rated their leg pain on a scale from 0-10, with a score of 0 representing "no pain" and a score of 10 representing "pain as bad as it could be."
Right Leg Pain in Numerical Rating Scales (NRS)
Right leg pain was measured using NRS. Patients rated their leg pain on a scale from 0-10, with a score of 0 representing "no pain" and a score of 10 representing "pain as bad as it could be."

Full Information

First Posted
August 15, 2007
Last Updated
December 6, 2017
Sponsor
Medtronic Spine LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT00517751
Brief Title
Condition of Approval Study
Acronym
COAST
Official Title
Treatment of Lumbar Spinal Stenosis With X-STOP® PEEK Spacer in Moderately Symptomatic Patients
Study Type
Interventional

2. Study Status

Record Verification Date
January 2016
Overall Recruitment Status
Terminated
Why Stopped
Due to Medtronic's voluntary withdrawal of PMA P040001 for X-STOP systems; post-approval study costs outweighed business benefits for marketing X-STOP in US.
Study Start Date
August 2007 (undefined)
Primary Completion Date
February 2015 (Actual)
Study Completion Date
April 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medtronic Spine LLC

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This prospective, multicenter longitudinal five-year study of X-STOP PEEK usage in LSS patients is designed to supplement pre-market safety and effectiveness data with information on longer-term device performance in a population of patients with moderately impaired physical function at preoperative baseline (i.e., an "indicated" population) who elect to undergo X STOP PEEK surgery.
Detailed Description
This prospective, multicenter longitudinal five-year study of X-STOP PEEK implant usage in LSS patients is designed to supplement pre-market safety and effectiveness data with information on longer-term device performance in a population of patients with moderately impaired physical function at preoperative baseline (i.e., an "indicated" population) who elect to undergo X-STOP PEEK surgery. This post-approval study will enroll 240 patients at up to 8 clinical sites where all participating spine surgeons have completed a company-sponsored physician training program. The clinical sites recruited to participate in this study comprise a geographically diverse mix of academic, referral, and/or community based sites. Safety and effectiveness data will be assessed at baseline and annually through five (5) years postoperatively. Office visits will be scheduled preoperatively, and at 6 weeks, 1, 2, 3, 4, and 5 years postoperatively. Clinical/neurological and radiographic examination will be performed during each office visit. A baseline patient history (including medication usage) will be taken, and concomitant medications will be recorded at each postoperative follow-up visit. In addition, patients will be asked to complete the following questionnaires prior to consultation with their physicians or their staff: Zurich Claudication Questionnaire (ZCQ), Oswestry Disability Index (ODI), Numeric Rating Scale (NRS), and SF-36 Health Survey. At the 2-, 3-, 4- and 5-year office visit, patients will also be asked two questions assessing the value of surgery and the overall improvement in the quality of life postoperatively. The primary study endpoint in this study is treatment success. Secondary endpoints will include scores from the SF-36, ODI, and NRS, as well as incidence rates of adverse events, device failures, and secondary surgeries.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lumbar Spinal Stenosis
Keywords
Lumbar Spinal Stenosis, X-STOP Spacer, Interspinous process decompression, Neurogenic Intermittent Claudication

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
176 (Actual)

8. Arms, Groups, and Interventions

Arm Title
X-STOP PEEK
Arm Type
Experimental
Arm Description
In this arm, patients will undergo X-STOP PEEK surgery.
Intervention Type
Device
Intervention Name(s)
X-STOP PEEK
Intervention Description
Placement of X-STOP PEEK in up to two levels in the lumbar spine for patients diagnosed with moderately symptomatic lumbar spinal stenosis in accordance with current labeling instructions for use.
Primary Outcome Measure Information:
Title
Treatment Success Rate at 24 Months
Description
Treatment success rate is reported as the percentage of participants who met all of the following criteria: Clinically significant improvement (by at least 0.5 points) in the Symptom Severity (SS) domain of the Zurich Claudication Questionnaire (ZCQ) compared to preoperative baseline Clinically significant improvement (by at least 0.5 points) in the Physical Function (PF) domain of the ZCQ compared to pre-operative baseline Patient satisfaction with treatment defined as a Patient Satisfaction (PS) score < 2.5 No additional surgery for lumbar stenosis performed Maintenance of distraction No dislodgement of the implant No device-related complications
Time Frame
24 months
Secondary Outcome Measure Information:
Title
Treatment Success Rate at 60 Months
Description
Treatment success rate is reported as the percentage of participants who met all of the following criteria: Clinically significant improvement (by at least 0.5 points) in the Symptom Severity (SS) domain of the ZCQ compared to preoperative baseline Clinically significant improvement (by at least 0.5 points) in the Physical Function (PF) domain of the ZCQ compared to pre-operative baseline Patient satisfaction with treatment defined as a Patient Satisfaction (PS) score < 2.5 No additional surgery for lumbar stenosis performed Maintenance of distraction No dislodgement of the implant No device-related complications
Time Frame
60 months
Title
Symptom Severity (SS) Scores Measured by Zurich Claudication Questionnaire (ZCQ)
Description
ZCQ is a validated outcomes instrument specific to lumbar spinal stenosis, and captures data in 3 distinct domains: SS, PF, and post-treatment PS. SS Score is based on seven questions (overall pain, pain frequency, pain in the back, pain in the leg, numbness, weakness, and balanced disturbance) in ZCQ. The first 6 questions are scored 1 to 5. Balance disturbance is scored in a 1-3-5 scale. The SS score is the mean of all answered items in the questionnaire, ranging from 1 to 5. A lower score represents a better outcome/condition. If more than two items were missing, the SS score was considered as missing.
Time Frame
Baseline, 6 weeks, 12 months, 24 months, 36 months, 48 months, and 60 months
Title
Success Rate in Symptom Severity (SS) Domain of Zurich Claudication Questionnaire (ZCQ)
Description
Success rate in SS domain of ZCQ is reported as percentage of participants who had success in SS domain of the ZCQ. The SS success was defined as clinically significant improvement by at least 0.5 point in SS score compared to preoperative baseline.
Time Frame
6 weeks, 12months, 24 months, 36 months, 48 months, and 60 months
Title
Physical Function (PF) Scores Measured by Zurich Claudication Questionnaire (ZCQ)
Description
PF score is the mean score of five physical function questions of ZCQ, ranging from 1 to 4. A lower score represents a better outcome/condition. If more than one item were missing, the PF score was considered as missing.
Time Frame
Baseline, 6 weeks, 12 months, 24 months, 36 months, 48 months, and 60 months
Title
Success Rate in Physical Function (PF) Domain of Zurich Claudication Questionnaire (ZCQ)
Description
Success rate in PF domain of ZCQ is reported as percentage of participants who had success in PF domain of ZCQ. The PF success was defined as clinically significant improvement by at least 0.5 points in PF score compared to preoperative baseline.
Time Frame
6 weeks, 12months, 24 months, 36 months, 48 months, and 60 months
Title
Patient Satisfaction (PS) Scores Measured by Zurich Claudication Questionnaire (ZCQ) at Post Treatment
Description
PS score is the mean score of 6 questions of ZCQ, ranging from 1 to 4 if the number of responses exceeded four. A lower score represents a better outcome. Patients with PS score less than 2.5 at postoperative evaluation were considered positive, which implied that patients were satisfied with their treatment.
Time Frame
6 weeks, 12 months, 24 months, 36 months, 48 months, and 60 months
Title
Success Rate in Patient Satisfaction (PS) Domain of Zurich Claudication Questionnaire (ZCQ) at Post Treatment
Description
Success rate in PS domain of ZCQ at post treatment is reported as the percentage of participants who had success in PS domain of ZCQ. The PS success was defined as PS score less than 2.5.
Time Frame
6 weeks, 12months, 24 months, 36 months, 48 months, and 60 months
Title
Oswestry Disability Index (ODI) Score
Description
ODI Questionnaire was used to assess patient back function. The ODI score ranges from 0-100. The best score is 0 (no disability) and worst is 100 (maximum disability).
Time Frame
Baseline, 6 weeks, 12 months, 24 months, 36 months, 48 months, and 60 months
Title
General Health Status -- SF-36 PCS
Description
The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) was used to assess general health status. The SF-36 results were summarized into two components, a physical component summary (PCS) and a mental component summary (MCS). The score for PCS is between 0 and 100, with higher scores denoting better quality of life.
Time Frame
Baseline, 6 weeks, 12 months, 24 months, 36 months, 48 months, and 60 months
Title
General Health Status -- SF-36 MCS
Description
MCS score is between 0 and 100, with higher scores denoting better quality of life.
Time Frame
Baseline, 6 weeks, 12 months, 24 months, 36 months, 48 months, and 60 months
Title
Back Pain in Numerical Rating Scales (NRS)
Description
Back pain was measured using NRS. Patients rated their back pain on a scale from 0-10, with a score of 0 representing "no pain" and a score of 10 representing "pain as bad as it could be."
Time Frame
Baseline, 6 weeks, 12 months, 24 months, 36 months, 48 months, and 60 months
Title
Left Leg Pain in Numerical Rating Scales (NRS)
Description
Left leg pain was measured using NRS. Patients rated their leg pain on a scale from 0-10, with a score of 0 representing "no pain" and a score of 10 representing "pain as bad as it could be."
Time Frame
Baseline, 6 weeks, 12 months, 24 months, 36 months, 48 months, and 60 months
Title
Right Leg Pain in Numerical Rating Scales (NRS)
Description
Right leg pain was measured using NRS. Patients rated their leg pain on a scale from 0-10, with a score of 0 representing "no pain" and a score of 10 representing "pain as bad as it could be."
Time Frame
Baseline, 6 weeks, 12 months, 24 months, 36 months, 48 months, and 60 months
Other Pre-specified Outcome Measures:
Title
Percent of Subjects With Pfirrmann Grades Increased From Baseline at Any Index Level at 24 Months
Description
The Pfirrmann Grading System is descriptive and grades the status on an intervertebral disc as visualized with MRI using a 5-point system (grade I, II, III, IV or V). Grade I: disc is homogeneous with bright hyper-intense white signal intensity and normal disc height. Grade V: disc is inhomogeneous with hypo-intense black signal intensity and there is no more distinction between the nucleus and annulus, the disc space is collapsed. The percent of subjects with Pfirrmann grades increased from baseline at 24 months is reported.
Time Frame
24 months
Title
Percent of Subjects With Pfirrmann Grades Increased From Baseline at Any Index Level at 60 Months
Description
The Pfirrmann Grading System is descriptive and grades the status on an intervertebral disc as visualized with MRI using a 5-point system (grade I, II, III, IV or V). Grade I: disc is homogeneous with bright hyper-intense white signal intensity and normal disc height. Grade V: disc is inhomogeneous with hypo-intense black signal intensity and there is no more distinction between the nucleus and annulus, the disc space is collapsed. The percent of subjects with Pfirrmann grades increased from baseline at 60 months is reported.
Time Frame
60 months
Title
Percent of Subjects With Pfirrmann Grades Increased at Adjacent Levels at 24 Months
Description
The percent of subjects with Pfirrmann grades increased from baseline at adjacent levels at 24 months is reported.
Time Frame
24 months
Title
Percent of Subjects With Pfirrmann Grades Increased at Adjacent Levels at 60 Months
Description
The percent of subjects with Pfirrmann grades increased from baseline at adjacent levels at 60 months is reported.
Time Frame
60 months
Title
Percent of Subjects Who Reported Implant-Related Adverse Events
Time Frame
Overall study period
Title
Percent of Subjects Who Had Any Subsequent Lumbar Spine Surgery
Time Frame
Overall study period

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: has a baseline score >2.0 in the Physical Function (PF) domain of the Zurich Claudication Questionnaire is 50 years old or older has leg/buttock/groin pain with or without back pain NOTE: Leg/buttock/groin pain must be completely relieved when flexed such as when sitting in a chair. If back pain is also present, it must be partially relieved when flexed. can sit for 50 minutes without pain can walk 50 feet or more has a confirmed diagnosis of neurogenic intermittent claudication secondary to lumbar spinal stenosis, with X-Ray, MRI and/or CT evidence of thickened ligamentum flavum, narrowed lateral recess and/or central canal narrowing has completed at least six months of conservative care therapy which may include but is not limited to physical therapy, bracing, systemic or injected medications has signed a patient informed consent document is physically and mentally willing and able or has a caregiver who can comply with the postoperative and routinely scheduled clinical and radiographic evaluations lives in the immediate area and has no plans to relocate to another geographic area before completion of the study or lives outside the immediate area and will comply with the scheduled postoperative visits with a prearranged and designated physician Exclusion Criteria: has a baseline score less than or equal to 2.0 in the Physical Function (PF) domain of the Zurich Claudication Questionnaire cannot sit for 50 minutes cannot walk more than 50 feet has unremitting pain in any spinal position has axial back pain only without leg/buttock/groin pain has a fixed motor deficit has cauda equina syndrome defined as neural compression causing neurogenic bowel (rectal incontinence) or bladder (bladder retention or incontinence) dysfunction has severe symptomatic lumbar spinal stenosis at more than two levels has significant instability of the lumbar spine, e.g., isthmic spondylolisthesis or degenerative spondylolisthesis greater than grade 1 (on a scale of 1 to 4) has an ankylosed segment at the affected level(s); has significant scoliosis (Cobb angle is greater than 25 degrees) has an acute fracture of the spinous process or pars interarticularis has sustained pathologic fractures of the vertebrae or multiple fractures of the vertebrae and /or hips has severe osteoporosis of the spine or hip, defined as bone mineral density (BMD) in the spine or hip more than 2.5 SD below the mean of adult normals in the presence of one or more fragility fractures has Paget's disease at the involved segment(s) or metastasis to the vertebrae has had any surgery of the lumbar spine has significant peripheral neuropathy demonstrated by nerve conduction velocity tests has acute denervation secondary to radiculopathy, as shown by EMG has significant peripheral vascular disease characterized by diminished dorsalis pedus or tibial pulses has extreme obesity as defined by a Body Mass Index (BMI) greater than 40 kg/m2 has an active systemic infection or infection localized to the site of implantation has an active systemic disease such as AIDS, HIV, hepatitis, etc. has a medical condition that may interfere with postoperative management and follow-up, or may result in patient death prior to study completion (e.g., Alzheimer's disease, unstable cardiac disease, active malignancy) has a recent history of narcotic abuse (i.e., within last 3 years) has a known allergy to titanium,titanium alloy, or polyetheretherketone is immunologically suppressed, or has received or is receiving steroids at any dose daily for more than one month within the last 12 months is currently involved in a study of another investigational product that may affect the outcome of this study is pregnant or planning to become pregnant during the study period cannot undergo MRI or tolerate closed MRI scanning.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jim Malcolm, MD
Organizational Affiliation
Pinnacle Orthopedics
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Kirklin Clinic - UAB Medical
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35249
Country
United States
Facility Name
Tucson Orthopaedic Institute-East Office
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85712
Country
United States
Facility Name
Tucson Orthopaedic Institute-Northwest Office
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85741
Country
United States
Facility Name
Silicon Valley Spine Institute
City
Campbell
State/Province
California
ZIP/Postal Code
95008
Country
United States
Facility Name
UC Davis Spine Center
City
Sacramento
State/Province
California
ZIP/Postal Code
95818
Country
United States
Facility Name
UCLA Comprehensive Spine Center
City
Santa Monica
State/Province
California
ZIP/Postal Code
90404
Country
United States
Facility Name
Colorado Neurosurgery Associates, P.C.
City
Denver
State/Province
Colorado
ZIP/Postal Code
80220
Country
United States
Facility Name
Panaorama Orthopedics and Spine Center
City
Golden
State/Province
Colorado
ZIP/Postal Code
80401
Country
United States
Facility Name
Yale School of Medicine, Dept. of Orthopaedics
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06520
Country
United States
Facility Name
George Washington University Hospital Medical Facility Associates
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20037
Country
United States
Facility Name
Pinnacle Orthopedics
City
Marietta
State/Province
Georgia
ZIP/Postal Code
30060
Country
United States
Facility Name
Orthopaedic Center of Southern Illinois
City
Mount Vernon
State/Province
Illinois
ZIP/Postal Code
62864
Country
United States
Facility Name
University of Kentucky, Dept of Neurosurgery
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40536-0298
Country
United States
Facility Name
Spine Institute of Louisiana
City
Shreveport
State/Province
Louisiana
ZIP/Postal Code
71101
Country
United States
Facility Name
Drisko, Fee & Parkins, P.C.
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
64116
Country
United States
Facility Name
UpState Orthopedics
City
East Syracuse
State/Province
New York
ZIP/Postal Code
13057
Country
United States
Facility Name
Mayfield Clinic
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45219
Country
United States
Facility Name
The Center Orthopedic & Neurosurgical Care & Research
City
Bend
State/Province
Oregon
ZIP/Postal Code
97701
Country
United States
Facility Name
NeuroSpine Institute
City
Eugene
State/Province
Oregon
ZIP/Postal Code
97401
Country
United States
Facility Name
OrthopaediCare
City
Willow Grove
State/Province
Pennsylvania
ZIP/Postal Code
19090
Country
United States
Facility Name
Texas Back Institute
City
Plano, Denton, Mansfield
State/Province
Texas
ZIP/Postal Code
75093, 76208, 76063
Country
United States
Facility Name
Neurosurgical Associates of San Antonio
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78258
Country
United States
Facility Name
Scott & White Memorial Hospital & Scott, Sherwood & Brindley Foundation
City
Temple
State/Province
Texas
ZIP/Postal Code
76508
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
15959362
Citation
Zucherman JF, Hsu KY, Hartjen CA, Mehalic TF, Implicito DA, Martin MJ, Johnson DR 2nd, Skidmore GA, Vessa PP, Dwyer JW, Puccio ST, Cauthen JC, Ozuna RM. A multicenter, prospective, randomized trial evaluating the X STOP interspinous process decompression system for the treatment of neurogenic intermittent claudication: two-year follow-up results. Spine (Phila Pa 1976). 2005 Jun 15;30(12):1351-8. doi: 10.1097/01.brs.0000166618.42749.d1.
Results Reference
background
PubMed Identifier
17176013
Citation
Hsu KY, Zucherman JF, Hartjen CA, Mehalic TF, Implicito DA, Martin MJ, Johnson DR 2nd, Skidmore GA, Vessa PP, Dwyer JW, Cauthen JC, Ozuna RM. Quality of life of lumbar stenosis-treated patients in whom the X STOP interspinous device was implanted. J Neurosurg Spine. 2006 Dec;5(6):500-7. doi: 10.3171/spi.2006.5.6.500.
Results Reference
background
PubMed Identifier
16826002
Citation
Kondrashov DG, Hannibal M, Hsu KY, Zucherman JF. Interspinous process decompression with the X-STOP device for lumbar spinal stenosis: a 4-year follow-up study. J Spinal Disord Tech. 2006 Jul;19(5):323-7. doi: 10.1097/01.bsd.0000211294.67508.3b.
Results Reference
background

Learn more about this trial

Condition of Approval Study

We'll reach out to this number within 24 hrs